Skip to main content

Market Overview

Veracyte Seeks To Raise $400M To Fund Decipher Biosciences Deal

  • Veracyte Inc (NASDAQ: VCYT) has commenced an underwritten public offering of $400 million in common stock. Underwriters have an option to purchase up to an additional $60 million shares.
  • Veracyte will use proceeds to finance its Decipher Biosciences acquisition announced yesterday and working capital and other general corporate purposes.
  • Goldman Sachs and SVB Leerink are acting as joint lead book-running managers for the offering.
  • Price Action: VCYT closed 13.47% higher at $73.79 on Wednesday.

Related Articles (VCYT)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Offerings General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at